Serum androsterone glucuronide (AoG) is a metabolite of circulating androgens under the influence of 5α-reductase activity and has been shown to be particularly elevated in women with acne. In this study, we wanted to evaluate changes in AoG before and after treatment with an oral contraceptive or placebo, and to assess whether changes correlated with the number and type of acne lesions. In order to accomplish these aims, we obtained sera from a completed prospective randomized trial, which was designed to assess the effectiveness of an oral contraceptive compared to placebo. Assessments were carried out in 56 women with moderate acne who were treated with Ortho Tri-Cyclen (norgestimate and ethinylestradiol) (30 patients) or placebo (26 patients) for 6 months. Before and after treatment, the number and type of skin lesions, serum levels of total T, free-T, DHEAS and AoG were determined. Serum AoG increased significantly in women with moderate acne, although T, free-T and DHEAS were normal. 75% of acne patients had elevated levels of serum AoG. Ratios of serum AoG to androgen precursors were also elevated. Oral contraceptive (OC) treatment significantly reduced levels of free-T and AoG, both of which were unaffected by placebo. While both OC and placebo treatment resulted in improvement of comedones and inflammatory lesions, OC treatment decreased inflammatory lesions to a greater extent (p<0.05). After treatment, serum AoG correlated with the number of inflammatory lesions. Results showed that serum AoG is a sensitive marker of acne in women, even in those with normal circulating precursor androgens; and is lowered by OC treatment, correlating with the reduction of inflammatory lesions. We hypothesize that the increase of serum AoG in normoandrogenic acne may be related to inflammation, and serum AoG may serve as a marker of this process.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Carmina E., Lobo R.A. Hirsutism, alopecia and acne. In: Becker K.L. (Ed.), Principles and Practice of Endocrinology and Metabolism. Lippincott Co. Pub., 3rd edition, Philadelphia, 2001, p. 991.
Lucky A.W., McGuire J., Rosenfield R.L., Lucky P.A., Rich B.H. Plasma androgens in women with acne vulgaris. J. Invest. Dermatol. 1983, 81: 70–74.
Hammerstein J., Moltz L., Schwatz U. Antiandrogens in the treatment of acne and hirsutism. J. Steroid Biochem. 1983, 19: 591–597.
Lemay A., Dewailly D., Grenier R., Huard J. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethinylestradiol and l-norgestrel. J. Clin. Endocrinol. Metab. 1990, 71: 8–14.
Lookingbill D.P., Horton R., Demers L.M., Egan N., Marks J.G., Santen R.J. Tissue production of androgens in women with acne. J. Am. Acad. Dermatol. 1985, 12: 481–487.
Thiboutot D., Harris G., Iles V., Cimis G., Gilliland K., Hagari S. Activity of the type 1 5-alpha-reductase exhibits regional differences in isolated sebaceouse glands and whole skin. J. Invest. Dermatol. 1995, 94: 279–283.
Marynik S.P., Chakmakjian Z.H., McCaffree D.L., Herndon J.H. Androgen excess in cystic acne. N. Engl. J. Med. 1983, 308: 981–986.
Vexiau P., Husson C., Chivot M., Breault J.L. Androgen excess in women with acne alone compared with women with acne and/or hirsutism. J. Invest. Dermatol. 1990, 94: 279–283.
Carmina E., Stanczyk F.Z., Matteri R.K., Lobo R.A. Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women. Fertil. Steril. 1991, 55: 871–876.
Slayden S.M., Moran C., Sams W.M., Boots L.R., Azziz R. Hyperandrogenemia in patients presenting with acne. Fertil. Steril. 2001, 75: 889–892.
Carmina E., Lobo R.A. Evidence for increased androsterone metabolism in some normoandrogenic women with acne. J. Clin. Endocrinol. Metab. 1993, 76: 1111–1114.
Carmina E., Gentzschein E., Stanczyk F.Z., Lobo R.A. Substrate dependency of C19 conjugates in hirsute hyperandrogenic women and the influence of adrenal androgen. Hum. Reprod. 1995, 10: 299–303.
Redmond G.P., Olson W.H., Lippman J.S., Kafrissen M.E., Jones T.M., Jorizzo J.L. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial. Obstet. Gynecol. 1997, 89: 615–622.
Lucky A.W., Henderson T.A., Olson W.H., Robisch D.M., Lebwohl M., Swinyer L.J. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J. Am. Acad. Dermatol. 1997, 37: 746–754.
Aydinlik S., Lachnit-Fixson U., Lehnert J. Reduced estrogen ovulation inhibitor in acne therapy: Double-blind study comparing Diane-35 to Diane. Fortschr. Med. 1986, 104: 547–550.
Carmina E., Ferin M., Lobo R.A. Evidence that insulin and androgens may participate in the regulation of serum leptin levels in women. Fertil. Steril. 1999, 72: 426–431.
Matteri R.K., Stanczyk F.Z., Gentzschein E.E., Delgado C., Lobo R.A. Androgen sulphate and glucuronide con- jugates in non-hirsute and hirsute women with polycystic ovary syndrome. Am. J. Obstet. Gynecol. 1989, 161: 1704–1709.
Carmina E. A risk-benefit assessment of pharmacological therapies for hirsutism. Drug Saf. 2001, 24: 267–276.
This study was funded by Ortho-McNeil Pharmaceutical Corporation, Raritan, NJ
About this article
Cite this article
Carmina, E., Godwin, A.J., Stanczyk, F.Z. et al. The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne1 . J Endocrinol Invest 25, 765–768 (2002). https://doi.org/10.1007/BF03345509
- androsterone glucuronide